⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5431066 | 0.93 | TSHR (0.40) | — | |
| SCHEMBL27184132 | 0.93 | TSHR (0.40) | — | |
| SCHEMBL27150426 | 0.90 | TSHR (0.39) | — | |
| SCHEMBL5423967 | 0.89 | TSHR (0.41) | — | |
| SCHEMBL343237 | 0.89 | — | — | |
| SCHEMBL625429 | 0.89 | — | — | |
| SCHEMBL303389 | 0.89 | TSHR (0.41) | — | |
| SCHEMBL1796331 | 0.89 | — | — | |
| SCHEMBL450925 | 0.87 | CYP2D6 (0.40) | — | |
| SCHEMBL31049944 | 0.87 | CYP2D6 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688784-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4688792-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | claimed |
| US-20250263412-A1 | NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-08-21 | — | — | US | claimed |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-08-05 | — | — | US | claimed |
| EP-4419207-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | claimed |
| EP-4554939-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-05-21 | — | — | EP | claimed |
| CN-119661543-A | Preparation method of 2-Boc-2, 7-diaza-spiro [4.4] nonane | 无锡科华生物科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| US-20250090524-A1 | BTK INHIBITORS | BIOGEN MA INC. | 2025-03-20 | — | — | US | claimed |
| CN-119604494-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2025-03-11 | — | — | CN | claimed |
| EP-3430013-A1 | CARBAPENEM COMPOUNDS | Orchid Pharma Limited (IN) | 2019-01-23 | — | — | EP | claimed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | claimed |
| WO-2017158616-A1 | CARBAPENEM COMPOUNDS | ORCHID PHARMA LTD. (IN) | 2017-09-21 | — | — | WO | claimed |
| EP-2895484-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2015-07-22 | — | — | EP | claimed |
| EP-2776407-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2014043068-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-03-20 | — | — | WO | claimed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | claimed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | claimed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | claimed |